In patients with multiple myeloma and prostate cancer, extending the bisphosphonate dosing interval may help decrease medication-related morbidity without compromising therapeutic benefit.
View Article and Find Full Text PDFObjective: Nephritis has been rarely associated with methimazole, primarily in the development of nephrotic syndrome. We describe a case of acute kidney injury without evidence of nephrotic syndrome following methimazole initiation.
Methods: We present the relevant history, laboratory data, and nuclear medicine data and review relevant documentation from the literature.